BioSpace News Archive

Garsite, a leading manufacturer of aviation refueling and specialty pumping equipment, announces the launch of its line of disinfecting equipment.

PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm (“Wincal”), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value of PharmAbcine’s existing and future assets through R&D efforts. U

NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can a

Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, announced the appointment of John Brottem as the company’s new General Counsel.

Findings from open-label switch period of Early AMPLE study show that high efficacy responses observed at week 24 with Orencia were sustained through week 48 in early rheumatoid arthritis patients testing positive (seropositive) for certain autoantibodies

Novanta to Present at the William Blair 40 th Annual Growth Stock Conference on Tuesday, June 9, 2020

CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico.

Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy

cPass™ test can be performed within an hour in standard laboratories without the need for live virus

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the successful closing of its previously announced private placement of $16.0 million of common stock at a price of $1.00 per share (representing a 34% premium at signing) to Syntone Ventures LLC, a U.S